Table 2.
Variables | Normal controls (n=21) 1 |
Subjects in the suicide group (n=28) |
Overall ANOVA |
P value for Multiple comparison by groupb |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
With a history of MDD (n=11) 2 |
With a history of other psychiatric disorders (n=17) 3 |
||||||||||||
Mean | SD | Mean | SD | Mean | SD | df | F | P | 1 vs 2 | 1 vs 3 | 2 vs 3 | ||
Akt1 studies | |||||||||||||
Akt1 catalytic activityb Immunolabelingb |
100 | 15 | 55 | 16 | 59 | 15 | 2,46 | 44.78 | <.001 | <.001 | <.001 | .49 | |
p-Akt1 (Thr308) | 100 | 11 | 59 | 19 | 65 | 17 | 2,46 | 36.89 | <.001 | <.001 | <.001 | .23 | |
p-Akt1 (Ser473) | 100 | 13 | 63 | 18 | 59 | 13 | 2,46 | 46.29 | <.001 | <.001 | <.001 | .41 | |
PDK1 studies | |||||||||||||
Catalytic activityb | 100 | 19 | 68 | 10 | 62 | 14 | 2,46 | 32.32 | <.001 | <.001 | <.001 | .29 | |
p-PDK1 immunolabelingb | 100 | 17 | 73 | 24 | 69 | 13 | 2,46 | 16.19 | <.001 | <.001 | <.001 | .58 | |
PTEN studies | |||||||||||||
mRNAc | 495 | 82 | 932 | 131 | 958 | 177 | 2,46 | 69.85 | <.001 | <.001 | <.001 | .61 | |
Total PTEN immunolabelingb | 100 | 19 | 145 | 26 | 139 | 33 | 2,46 | 15.33 | <.001 | <.001 | <.001 | .60 | |
p-PTENd | |||||||||||||
1.02 | .22 | .72 | .12 | .71 | .21 | 2,46 | 14.53 | <.001 | <.001 | <.001 | .89 |
Data were analyzed using univariate analysis of variance (ANOVA). Bonferroni-adjusted P values were considered significant (P = .05/7 = .007).
Group 1 indicates normal controls; group 2, subjects in the suicide group with a history of MDD; and group 3, subjects in the suicide group with a history of other psychiatric disorders. bPercent of control;
attomoles/µg total RNA;
ratio to total PTEN